MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid

International Journal of Cancer

Volumn 116, Issue 5, 2005, Pages 824-829

  Huisman, Maarten T ^a,b   Chhatta, Aniska A ^b   Van Tellingen, Olaf ^a   Beijnen, Jos H ^c   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

ABCC2; Multidrug resistance; Paclitaxel; Probenecid; Stimulation

Indexed keywords

DOCETAXEL; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; INULIN; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL; PROBENECID; TAXANE DERIVATIVE; TRITIUM; VINBLASTINE;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; CANCER CELL; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG TRANSPORT; IC 50; INCUBATION TIME; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; CELL LINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PACLITAXEL; PROBENECID; TAXOIDS; VINBLASTINE;

EID: 23244451963     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21013     Document Type: Article

References (23)

1. Borst P, Oude Elferink RPJ. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
2. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997;94:2031-5.
3. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A, Flicker G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110:1309-18.
4. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999;104: 1441-7.
5. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
6. Mottino AD, Hoffman T, Jennes L, Vore M. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 2000;293:717-23.
7. Miller DS, Nobmann SN, Gutmann H, Toeroek M, Drewe J, Flicker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 2000;58:1357-67.
8. Sandusky GE, Mintze KS, Pratt SE, Dantzig AH. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 2002;41: 65-74.
9. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LCJM, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, Borst P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 1998;101:1310-9.
10. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-5.
11. Cui Y, König J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55: 929-37.
12. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S, Kuwano M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996;56:4124-9.
13. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, Akiyama S, Ono M, Kuwano M. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997;57:5475-9.
14. Huisman MT, Smit JW, Crommentuyn KML, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002;16:2295-301.
15. Zelcer N, Huisman MT, Reid G, Wielinga PR, Breedveld P, Kuil A, Knipscheer P, Schellens JHM, Schinkel AH, Borst P. Evidence for two interacting ligand-binding sites in human MRP2 (ABCC2). J Biol Chem 2003;278:23538-44.
16. Louvard D. Apical membrane aminopeptidase appears at site of cell-cell contact in cultured kidney epithelial cells. Proc Natl Acad Sci USA 1980;77:4132-6.
17. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1995;664:383-91.
18. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 2000;83:366-74.
19. Guo A, Marinaro W, Hu P, Sinko PJ. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 2002;30:457-63.
20. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 2000;83:375-83.
21. Kondratov RV, Komarov PG, Becker Y, Ewenson A, Gudkov AV. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc Natl Acad Sci USA 2001;98:14078-83.
22. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003;3:1-19.
23. Henness S, Davey MW, Harvie RM, Davey RA. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int J Radiat Oncol Biol Phys 2002;54:895-902.